Metastatic Prostate Cancer Research: PSMAfore follow-on study favors radioligand therapy over change to androgen receptor pathway inhibition

Follow-on analysis of results from the phase 3 PSMAfore study, along with the overall study results, support the consideration of 177Lu-PSMA-617 as a new standard treatment approach for this prevalent population of patients with mCRPC. Research led by Dana-Farber Cancer Institute and others.

Cedars-Sinai Experts Available for Interviews at American Urological Association Annual Meeting May 3-6

Physician-scientists from the Department of Urology at Cedars-Sinai will be attending the American Urological Association (AUA) Annual Meeting May 3-6 in San Antonio, Texas, and are available to discuss the latest research and innovations in urological care.

MD Anderson Research Highlights for April 24, 2024

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.

New urine-based test detects high-grade prostate cancer, helping men avoid unnecessary biopsies

Researchers at the University of Michigan Rogel Cancer Center have developed a new urine-based test that addresses a major problem in prostate cancer: how to separate the slow-growing form of the disease unlikely to cause harm from more aggressive cancer that needs immediate treatment.

Analysis Group Researchers Identify Racial Disparities in Treatment of Metastatic Castration-Sensitive Prostate Cancer

Researchers from Analysis Group, a global leader in health economics and outcomes research (HEOR), have coauthored the first large-scale study that revealed racial disparities in treatment, survival, and access to care among patients with metastatic castration-sensitive prostate cancer (mCSPC) since the first novel hormonal therapy was approved in 2018.

Sylvester Physician Co-Authors Global Plan to Combat Prostate Cancer

Annual prostate cancer cases worldwide are projected to double by the year 2040, and annual deaths are projected to increase by 85% – mainly among men in low- and middle-income countries. A commissioned report in The Lancet seeks to guide cancer experts worldwide on how to manage this massive influx of prostate cancer patients.

Moncrief Cancer Institute debuts new Mobile Screening Clinic funded by Tarrant County

Moncrief Cancer Institute debuted its new Mobile Screening Clinic prior to the Tarrant County Commissioners Court meeting today. The $1 million, 36-foot cancer screening clinic was funded by Tarrant County through a three-year, $9 million grant awarded to Moncrief Cancer Institute in 2022. Part of the federal funding Tarrant County received through the American Rescue Plan Act (ARPA), the grant enabled Moncrief to expand its comprehensive cancer screening program to more underserved residents in Tarrant County.

The gold standard: Nobel Prize gifted to Tulane University by Dr. Andrew Schally

Former Tulane University researcher Dr. Andrew Schally has donated his Nobel Prize to Tulane’s School of Medicine. Schally won the award in 1977 for identifying the presence of key peptides in the hypothalamus and successfully synthesizing them, research that led to advanced prostate cancer treatment methods.

Sandalwood Oil By-product Prevents Prostate Cancer Development in Mice

Sandalwood oil has been used worldwide for centuries. Now, a study is the first to demonstrate in vivo the chemo-preventive properties of a by-product of the oil in a mouse model. Results show administering alpha-santalol reduced visible prostate tumors, protected the normal tissue, and delayed progression from a precancerous condition to a high-grade form of cancer. These findings are significant because mortality in prostate cancer patients is mainly attributable to advanced stages of the disease.

Urology on the Beach Meeting Highlights Innovative Approaches to Multidisciplinary Care

Renowned urologists from leading academic centers shared their insights and clinical recommendations at Urology on the Beach, a three-day professional conference hosted by the Desai Sethi Urology Institute (DSUI) at the University of Miami Miller School of Medicine.

Precision medicine navigators increase genomic testing rates for Black patients with prostate cancer

The presence of a clinical navigator to act as a liaison between people with prostate cancer and the health care system greatly increases the likelihood that patients, especially Black patients, will receive advanced testing that can help predict the severity of their disease and guide treatment, a new study suggests.

High cure rate, low toxicity maintained with shortened radiation treatment for intermediate risk prostate cancer, study finds

People with intermediate risk, localized prostate cancer can be treated as effectively using fewer and higher doses of radiation therapy delivered over five treatment sessions as they can with lower doses delivered over several weeks, a new phase III randomized trial suggests.

Global Speakers, Cutting-edge Topics, Surgical Theater on Tap for Desai Sethi Urology Institute’s Urology on the Beach 2024

Desai Sethi Urology Institute at the University of Miami Miller School of Medicine will host its second annual, in-person Urology on the Beach meeting, January 19 to 21, 2024, at the Fontainebleau Hotel in Miami Beach.

Winners of the ASTRO-Sumitomo Pharma-Pfizer Alliance new combination therapy challenge announced

The American Society for Radiation Oncology (ASTRO) today announced the three winning research proposals for the 2022 ASTRO-Myovant Sciences (now known as Sumitomo Pharma)-Pfizer Alliance New Combination (Relugolix-Radiation) Therapy Challenge.

Desai Sethi Urology Institute Researcher Finds “Sneaky Testosterone” Might Signal Worse Outcomes for Men with Prostate Cancer

Findings from the newly published study in The Journal of Clinical Investigation suggest a large proportion of men have testosterone concentrations that are much higher in and around the prostate than traditional blood draws suggest. And this elevated exposure near the prostate increases the risk of poor outcomes after surgical removal of the prostate gland.

September is Prostate Cancer Awareness Month: Know the Warning Signs, When to Get Screened and Important New Treatments

Renowned prostate cancer researcher Dr. Lorelei Mucci is the director of strategic research partnerships at the American Cancer Society. Her role includes leading an ACS initiative called IMPACT, or “Improving Mortality Toward Prostate Cancer Together” to address the alarming negative trends in prostate cancer incidence and disparities. For Prostate Cancer Awareness Month Dr. Mucci reviews the signs and symptoms of prostate cancer, including important information about risk factors, PSA screening, and more.

Sylvester Comprehensive Cancer Center Tip Sheet – August 2023

New research shows blood cancers are often misdiagnosed, an NCI grant to develop a urine test for prostate cancer, a surgeon-scientist receives Sylvester’s first DoD grant to study pancreatic cancer, bolstering emergency preparedness for climate-driven disasters, and more are included in this month’s tip sheet .

Renowned Urologic Specialist to Lead UCSF Urology Program

Benjamin N. Breyer, MD, MAS, FACS, a renowned leader in urology and urological surgery, has been appointed chair of the UCSF Department of Urology. Breyer is a urologic surgeon who is internationally known for performing complex urethral and penile reconstruction for urethra stricture and cosmetic disfigurement, male incontinence, male fistula, and surgery for erectile dysfunction.

In preclinical study, Sylvester researchers target treatment-resistant prostate cancer with oral chemotherapy that works 2 ways

Researchers at Sylvester Comprehensive Cancer Center have developed a first-of-its-kind, orally administered drug to disrupt prostate cancer cells’ metabolism and deliver the chemotherapy agent cisplatin directly into treatment-resistant prostate cancer cells. The compound – Platin-L – works in two ways, breaking down a process that malignant prostate cancer cells use to fuel their growth, and delivering cisplatin directly into treatment-resistant cancer cells.

A new study validates the first-ever predictive AI biomarker of androgen deprivation therapy (ADT) benefit in prostate cancer

Data from a new study published in NEJM Evidence shows promise for personalized use of short term ADT in men with predominantly intermediate-risk prostate cancer. The information validates the first-ever predictive AI biomarker of androgen deprivation therapy (ADT) benefit in prostate cancer.

Study reveals how treatment-resistant prostate cancer provides its own hormonal fuel

A new study in mice, led by researchers at Washington University School of Medicine in St. Louis, explains how prostate cancer senses a drop in testosterone levels due to common anti-hormone therapy and then begins making cholesterol — a necessary precursor to testosterone — to generate its own testosterone to fuel tumor growth. The study also points to a possible drug combination that may stop the cancer from feeding its own growth.

MD Anderson Research Highlights for June 7, 2023

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.

ASCO23: Sylvester Cancer Experts Available for Interviews on a Wide Range of Topics

In addition to presenting Sylvester Comprehensive Cancer Center research findings, Sylvester experts are available at ASCO to share perspectives on a wide variety of topics and studies ranging from breast cancer to sarcoma, prostate cancer, mesothelioma, melanoma, CNS tumors and more.

New Study by Sylvester Investigators Indicates Treatment Patterns, Not Genetics, Drive Prostate Cancer Disparities

A large-scale retrospective analysis by researchers with the Sylvester Comprehensive Cancer Center suggests that differences in care, rather than genetics, likely explain disparities in advanced prostate cancer between men of African and European ancestry. The study of almost 13,000 men with advanced prostate cancer, published today in The Lancet Digital Health is one of the most comprehensive studies to date of prostate cancer disparities between men of these ethnicities.

Desai Sethi Urology Institute Presents, Debates and is Recognized at AUA 2023

A banner year for Desai Sethi Urology Institute at urology’s premier meeting, the American Urological Association (AUA) 2023, held April 28-May 1 in Chicago where faculty and researchers led and debated during plenary sessions and presented novel research in topics spanning prostate and bladder cancers to sexual function and robotic surgery.

Moffitt Researchers Develop CAR T Cells that Fight Prostate Cancer in Bone

Prostate cancer frequently metastasizes to the bone and is incurable. Moffitt Cancer Center researchers are working to identify new treatment options for this subset of patients. In a new article published today in Science Advances, a team of Moffitt scientists demonstrates that chimeric antigen receptor T-cell (CAR T) therapy is an effective antitumor approach in mouse models of bone metastatic prostate cancer.